All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Elromo 50mg Tablet
Prescription Required
Salt Composition : Eltrombopag
Manufacturer : ZYDUS CADILA
Origin of Medicine : India
7 Tablet(s) In A Strip
Introduction to Elromo 50mg Tablet
Elromo 50mg Tablet is an anticoagulant drug belonging to the thrombopoietin (TPO) receptor agonist category, containing the active ingredient Eltrombopag. It treats low platelet counts caused by primary immune thrombocytopenia (ITP) or hepatitis C (HCV) infection. ITP refers to an autoimmune disorder in which the immune system destroys platelets. Platelets are blood cells that aid in clotting and protect blood vessel walls. When platelet levels are low, it can result in severe bleeding and bruising. This tablet is also used in adults to treat low blood counts caused by severe aplastic anaemia (a serious blood disease that occurs when the bone marrow fails to produce enough new blood cells).
This drug should not be used in individuals with known hypersensitivity or allergic reactions to the drug or its components. Allergic reactions can range from mild to severe and may include symptoms such as rash, itching, swelling, dizziness, or difficulty breathing. Elromo 50mg Tablets are contraindicated in patients with severe liver impairment or active liver disease. This drug can potentially cause hepatotoxicity, as increased liver enzymes and bilirubin levels indicate. Using this drug in individuals with severe liver disease can further worsen liver function, so caution is advised. Your doctor will recommend that you are checked for cataracts. Your doctor should arrange regular testing if you do not have routine eye tests. You may also be checked for bleeding in or around your retina (the light-sensitive layer of cells at the back of the eye).
If you stop taking this tablet, your blood platelet count is likely to become low again within several days. The platelet count will be monitored, and your doctor will discuss appropriate precautions. A very high blood platelet count may increase the risk of blood clotting. However, blood clots can also form with normal or even low platelet counts. Your doctor will adjust your dose of this medicine to ensure that your platelet count does not become too high. Do not take this tablet with dairy products or drinks, as the calcium in these items affects the absorption of the medicine. Use effective birth control during the treatment, and if you become pregnant, you must inform your doctor. Elromo 50mg Tablets are not advised for children under one with ITP. It is also not recommended for patients under 18 with low platelet counts caused by hepatitis C or severe aplastic anaemia. Tell your doctor if you are taking, have recently taken, or might take other medicines. It includes medicines obtained without a prescription and vitamins.
Uses of Elromo 50mg Tablet
Elromo 50mg Tablet is used to treat,
- Low platelet counts are caused by primary immune thrombocytopenia (ITP) or hepatitis C virus (HCV) infection.
- Severe aplastic anemia
Therapeutic Effects of Elromo 50mg Tablet
Elromo 50mg Tablets stimulate megakaryocytes (the large bone marrow cells) responsible for producing platelets. By raising the number of platelets in the blood, this drug prevents bleeding and bruising.
Interaction of Elromo 50mg Tablet with other drugs
Inform your healthcare provider about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications include antacid medicines, statins, ciclosporin, methotrexate, topotecan, lopinavir, or ritonavir, and vitamin and mineral supplements may interact with Elromo 50mg Tablet and reduce effectiveness by causing undesirable side effects.
More Information about Elromo 50mg Tablet
- Store Elromo 50mg Tablet at room temperature (25°C).
- Keep the medicine out of reach of children and pets.
How to consume Elromo 50mg Tablet
It is an orally available prescription drug. Your doctor will decide the dose and duration of the drug based on the disease condition and other factors. Always take an Elromo 50mg Tablet as prescribed by your doctor. Take the tablet with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water.
Safety Advices for Elromo 50mg Tablet
Pregnancy
Elromo 50mg Tablet is not recommended for pregnant patients because it may cause fetal harm. You must inform your doctor if you are pregnant, suspecting, or planning to get pregnant during the treatment.
Breast Feeding
It is not known whether Elromo 50mg Tablet passes into breast milk. If you are breastfeeding or planning to breastfeed, tell your doctor.
Lungs
It is unknown whether Elromo 50mg Tablet can be prescribed for patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Liver
Elromo 50mg Tablet should be cautiously administered in patients with severe liver diseases. Dose adjustments are necessary for severe liver failure. Inform your doctor if you have liver issues before initiating the therapy.
Alcohol
It is unknown whether alcohol may interact with the Elromo 50mg Tablet. Inform your physician if you drink alcoholic beverages.
Driving
Driving vehicles or operating heavy machinery is unsafe after taking the Elromo 50mg Tablet. It may cause dizziness and impair concentration.
Side Effects of Elromo 50mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Common
- Nausea
- Diarrhea, abdominal pain
- Common cold
- Cough
- Respiratory tract infection
- Back pain
- High temperature, cough
- Loss of appetite
- Hair loss
- Swelling in feet or hands
- Headache, dizziness
- Mouth and throat pain
- Joint pain
Word of Advice
Ensure that in the 2 hours after or 4 hours before you take this medication, you don’t consume dairy foods (such as cheese or butter), milk or milkshakes, antacids, and supplements containing iron, aluminum, magnesium, calcium, selenium, zinc, or calcium. If you forget to take the Elromo 50mg Tablet, take your next dose at the usual time. Do not take more than one dose of this drug daily. Don’t stop taking this tablet without talking to your doctor. If your doctor advises you to stop treatment, your platelet count will be checked each week for four weeks. If you have any doubts regarding the use of this medicine, ask your doctor.
FAQs
Q 1. What is ITP?
Immune thrombocytopenia, also known as ITP, is a rare blood disorder. People with ITP have insufficient platelets in their blood. A low platelet count can cause bruising and bleeding.
Q 2. Who should not use the Elromo 50mg Tablet?
People with immune (primary thrombocytopenia (ITP) and children under one should not use Elromo 50mg Tablets. It is also not suggested for people with severe aplastic anemia and hepatitis C.
Q 3. Will you be monitored during treatment with the Elromo 50mg Tablet?
Yes, you will be monitored during the Elromo 50mg Tablet. Your healthcare provider will regularly access your white blood cell, platelets, blood clotting factors, heart rate, eye test, and complete blood count.
Q 4. Is it safe to take a Elromo 50mg Tablet on an empty stomach?
Yes, Elromo 50mg Tablets should be taken on an empty stomach. Because antacids, mineral and vitamin supplements (iron, calcium, magnesium, aluminum, selenium, and zinc), dairy products, calcium-enriched foods, and fortified juices interfere with this drug absorption. So, please take them at least two hours before or four hours after taking the medication.
Q 5. What happens if you discontinue using the Elromo 50mg Tablet?
If you discontinue using Elromo 50mg Tablets suddenly, it decreases platelet count as it can lead to severe bleeding. However, telling your healthcare practitioner before discontinuing this medication is advisable.
Q 6. How to store a Elromo 50mg Tablet?
Store Elromo 50mg Tablet at 25°C and out of the reach of children. After the expiration date, do not use this medication.
Fact Box of Elromo 50mg Tablet
| Molecule name: Eltrombopag | Therapeutic class: Anticoagulant |
| Pharmacological class: Thrombopoietin (TPO) receptor agonist | Indications: 1. Low platelet counts caused by immune primary thrombocytopenia (ITP) or hepatitis C virus (HCV) infection. 2. Severe aplastic anaemia. |
References
- Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on Jan 2022] [Accessed on 22 May 2023], https://www.medicines.org.uk/emc/files/pil.508.pdf
- GlaxoSmithKline, US Food and Drug Administration, [ Revised on October 2008] [Accessed on 22 May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf
- Revolade, Annex I summary of Product Characteristics - European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf [Accessed on 22 May 2023].
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
